Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    -0.50 (-0.75%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.24m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

PCA Dealing

12 Feb 2026 17:40

RNS Number : 8457S
Venture Life Group PLC
12 February 2026
 

12 February 2026

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

PCA Dealing

 

Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that it was notified on 11 February 2026 that Lewis Arthur, a PCA of Sarah Arthur, Interim Commercial Director of the Company, purchased 2,959 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a price of 67.38p per Ordinary Share on 29 January 2026 (the "Purchase").

Following the Purchase, Sarah Arthur's beneficial interest in the Company, including those held by her PCA, is 2,959 Ordinary Shares, representing 0.002 per cent. of the issued share capital of the Company.

 

For further information, please contact:

Venture Life Group PLC +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 The notification below, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail on the share dealings.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Lewis Arthur

2

 

Reason for the notification

 

a)

 

Position/status

 

PCA of Sarah Arthur, Interim Commercial Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

67.38 pence

2,959

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - Single transaction

 

 

 

 

 

 

e)

 

Date of the transaction

 

29 January 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXAAFDPKEFA
Date   Source Headline
3rd May 20167:00 amRNSFirst distribution agreements signed for UltraDEX
31st Mar 20167:00 amRNSDistribution Deals on Benecol 'once a day' Sachet
29th Mar 20167:02 amRNSNotice of Results
18th Mar 201611:04 amRNS'1000 Companies to Inspire Britain 2016' report
7th Mar 20167:00 amRNSCompletion of Acquisition
3rd Mar 20167:00 amRNSDirector/PDMR Shareholding
1st Mar 201612:07 pmRNSResult of General Meeting and Issue of Equity
18th Feb 201610:20 amRNSDirectorate Change
12th Feb 20165:38 pmRNSCircular Publication & Notice of General Meeting
12th Feb 201612:11 pmRNSResults of Placing to Partially Fund Acquisition
12th Feb 20167:00 amRNSProposed Placing and issue of Convertible Bonds
13th Jan 20167:00 amRNSProduct Launch
23rd Dec 20157:38 amRNSTrading Update
29th Sep 20157:00 amRNSInterim Results
9th Sep 20157:00 amRNSNotice of Results
9th Jul 20157:00 amRNSPre-Close Trading Statement
10th Jun 201511:41 amRNSAGM Statement
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
22nd May 20157:00 amRNSPDMR Shareholding
15th Apr 20157:00 amRNS2014 Annual Report and Dividend Timetable
25th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSSale of trademarks: manufacturing agreement signed
26th Jan 20157:00 amRNS30-year exclusive distribution deal signed
9th Dec 20147:00 amRNSBenecol Supplement Capsule Sale Malta
4th Dec 201411:54 amRNSHolding(s) in Company
28th Nov 20147:00 amRNSShare Placing
19th Nov 20147:00 amRNSAppointment of Nominated Adviser and Broker
10th Oct 20147:00 amRNSDirector's Dealings
8th Oct 20147:00 amRNSDirector Dealings
6th Oct 20147:00 amRNSDirectors' Dealings
1st Oct 20147:00 amRNSInvestor Forum
29th Sep 20147:00 amRNSInterim Results
23rd Sep 20147:00 amRNSNew distribution agreements
5th Sep 20147:00 amRNSNotice of Interim Results
6th Aug 20147:00 amRNSNew Product Development and Board Change
7th Jul 20147:00 amRNSNew distribution agreement signed
30th Jun 201412:09 pmRNSAGM Statement
30th Jun 20147:00 amRNSTotal Voting Rights
25th Jun 20147:00 amRNSNew distribution agreements signed
17th Jun 20147:00 amRNSAppointment of Non-Executive Director
13th Jun 20149:44 amRNSHolding(s) in Company
5th Jun 20147:01 amRNSIssue of new shares
5th Jun 20147:00 amRNSFinal Results
23rd Apr 20147:00 amRNSNew Distribution Agreement
28th Mar 20148:00 amRNSAdmission to AIM and Acquisition of Biokosmes Srl

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.